Tradestie Institutional Equity Comparison Engine

IBRX vs PVLA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

IBRX Overall Edge

IBRX Captures Institutional Edge (3โ€“1 Pillars ยท 6โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to ImmunityBio, Inc. Common Stock (IBRX) driven by superior Valuation, Growth & Margin, Momentum & Technical while PVLA counters with relative strength in Options & Structure. Fundamentally, IBRX trades at 66.7x Forward P/E with -150.2% operating margin (+52.3% YoY revenue) versus PVLA at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, IBRX sits in BREAKDOWN (16th %ile IV; Dealer Gamma Walls on Pro) against PVLA sits in CONSOLIDATION (2nd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner IBRX
IBRX 66.7x vs PVLA N/M Fwd P/E
Growth & Margin Winner IBRX
Op Margin -150.2% vs 0.0% ยท YoY +52.3% vs +0.0%
Momentum & Technical Winner IBRX
1Y +201.2% vs +80.2% ยท 52W Pos 39% vs 68%
Options & Structure Winner PVLA
BREAKDOWN (16th %ile IV) vs CONSOLIDATION (2nd %ile IV)
IBRX NASDAQ
ImmunityBio, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$6.03
+0.08% 1D
Market Cap $6.5B
1M Return -34.37%
1Y Return +201.25%
Forward P/E 66.7x
Unified AI Score
52.8 / 100 HOLD
Tech 53.0 Fund 56.0 Flow 69.0 Mom 60.0
PVLA NASDAQ
Palvella Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$145.03
-4.89% 1D
Market Cap $2.2B
1M Return +20.56%
1Y Return +80.16%
Forward P/E N/M
Unified AI Score
48.2 / 100 HOLD
Tech 35.0 Fund 53.0 Flow 67.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: IBRX +201.25% PVLA +80.16% Spread: +121.09 pp (IBRX Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period IBRX Revenue PVLA Revenue IBRX Op. Margin PVLA Op. Margin Margin Edge
FY2018 $0M $30M -209338.3% -113.1% PVLA
FY2019 $0M $40M -7095.9% -62.2% PVLA
FY2020 $0M $30M -36509.1% -115.7% PVLA
FY2021 $0M $30M -35361.9% -165.0% PVLA
FY2022 $0M $30M -146374.2% -167.8% PVLA
FY2023 $0M $40M -58239.5% -27.7% PVLA
FY2024 $10M N/A -2334.2% N/A IBRX
FY2025 $110M N/A -226.0% N/A IBRX

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: IBRX (6) vs PVLA (3)
Institutional Metric IBRX PVLA Criterion Row Winner
Market Capitalization Scale $6.5B $2.2B Larger Scale IBRX
Trailing P/E Ratio Valuation 66.7x N/M Lower Multiple IBRX
Forward P/E Ratio Valuation 66.7x N/M Lower Multiple IBRX
Revenue Growth (YoY) Growth +52.3% +0.0% Higher Growth IBRX
Operating Margin (TTM) Profitability -150.2% 0.0% Higher Margin PVLA
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency 0.0% -63.4% Higher ROE IBRX
52-Week Range Position Momentum 39% ($2โ€“$12) 68% ($72โ€“$180) Stronger Trend PVLA
Beta / 30D Volatility Risk Regime 1.68ฮฒ ยท 103% Vol 1.66ฮฒ ยท 75% Vol Lower Realized Risk PVLA
Unified Institutional Score Composite Signal 52.8 / 100 (HOLD) 48.2 / 100 (HOLD) Higher Composite IBRX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full IBRX vs PVLA Buy Guide
IBRX BREAKDOWN
26d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 16th %ile
IV Regime Compressed (<25th %ile)
Live IBRX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
PVLA CONSOLIDATION
70d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 2nd %ile
IV Regime Compressed (<25th %ile)
Live PVLA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither IBRX nor PVLA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.